Palvella Therapeutics, Inc. PVLA
149.28 USD -3.20 (-2.10%)
As ofNov 16, 2026, 1:03 PM EST
149.04 Day range 157.00
72.23 52-week range 179.95
- YTD
- +42.62%
- 1 year
- +78.31%
News
benzinga.com Leerink Partners Initiates Coverage On Palvella Therapeutics with Outperform Rating, Announces Price Target of $228 Leerink Partners analyst Jenny Gonzalez-Armenta initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Outperform rating and announces Price Target of $228.
defenseworld.net Palvella Therapeutics, Inc. $PVLA Stock Bought by Alps Advisors Inc. Alps Advisors Inc. lifted its position in shares of Palvella Therapeutics, Inc. (NASDAQ: PVLA) by 33.0% in the third quarter, according to the company in its most recent 13F filing with the…
defenseworld.net 2,882 Palvella Therapeutics, Inc. $PVLA Shares Bought by Calamos Advisors LLC Calamos Advisors LLC raised its stake in shares of Palvella Therapeutics, Inc. (NASDAQ: PVLA) by 27.5% during the third quarter, according to the company in its most recent 13F filing with the SEC.…benzinga.com Canaccord Genuity Maintains Buy on Palvella Therapeutics, Raises Price Target to $243 Canaccord Genuity analyst Whitney Ijem maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $232 to $243.
benzinga.com Oppenheimer Maintains Outperform on Palvella Therapeutics, Raises Price Target to $232 Oppenheimer analyst Trevor Allred maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform and raises the price target from $210 to $232.
benzinga.com Palvella Therapeutics Q3 2026 Earnings Call Transcript Palvella Therapeutics (NASDAQ:PVLA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Palvella Therapeutics Q3 EPS $(1.70) Beats $(1.82) Estimate Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.70) per share which beat the analyst consensus estimate of $(1.82) by 6.59 percent. This is a 65.05 percent decrease over losses…
benzinga.com William Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating William Blair analyst Alethia Young initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Outperform rating.
